Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ANP-230 in infantile episodic limb pain
jRCT2061200046Phase 2Recruiting
- Sponsor
- AlphaNavi Pharma
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DSP-2230 in Infantile episodic limb pain (IELP) (4 arms), sponsored by AlphaNavi Pharma. Primary endpoints: Change in pain score from baseline (NRS-11) and Change in total duration and total number of pain attacks from baseline. Started Jan 2021; status: recruiting.
02
Drugs
DSP-2230
03
Conditions
Infantile episodic limb pain (IELP)
Beyond the preview
Go deeper on jRCT2061200046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200046.